Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Cell Procurement

Safety and preliminary efficacy of plerixafor (Mozobil) in combination with chemotherapy and G-CSF: an open-label, multicenter, exploratory trial in patients with multiple myeloma and non-Hodgkin's lymphoma undergoing stem cell mobilization

Bone Marrow Transplantation volume 45, pages 39–47 (2010)Cite this article

Abstract

Plerixafor, a novel CXCR4 inhibitor, is effective in mobilizing PBSCs particularly when used in conjunction with G-CSF. In four cohorts, this pilot study explored the safety of plerixafor mobilization when incorporated into a conventional stem cell mobilization regimen of chemotherapy and G-CSF. Forty (26 multiple myeloma and 14 non-Hodgkin's lymphoma) patients were treated with plerixafor. Plerixafor was well tolerated and its addition to a chemo-mobilization regimen resulted in an increase in the peripheral blood CD34+ cells. The mean rate of increase in the peripheral blood CD34+ cells was 2.8 cells/μl/h pre- and 13.3 cells/μl/h post-plerixafor administration. Engraftment parameters were acceptable after myeloblative chemotherapy, with the median day for neutrophil and plt engraftment being day 11 (range 8–20 days) and day 13 (range 7–77 days), respectively. The data obtained from the analysis of the cohorts suggest that plerixafor can safely be added to chemotherapy-based mobilization regimens and may accelerate the rate of increase in CD34+ cells on the second day of apheresis. Further studies are warranted to evaluate the effect of plerixafor in combination with chemomobilization on stem cell mobilization and collection on the first and subsequent days of apheresis, and its impact on resource utilization.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3

Similar content being viewed by others

References

  1. Hatse S, Balzarini J, Liekens S . Stromal cell-derived factor 1 (CXCL12) binds to endothelial cells and signals through a receptor different from CXCR4. Biochem Biophys Res Commun 2006; 348: 192–9.

    Article  CAS  PubMed  Google Scholar 

  2. Hendrix C, Collier A, Lederman M, Schols D, Pollard R, Brown S et al. Safety, pharmacokinetics, and antiviral activity of AMD3100, a selective CXCR4 receptor inhibitor, in HIV-1 infection. J Acquir Immune Defic Syndr 2004; 37: 1253–1262.

    Article  CAS  PubMed  Google Scholar 

  3. Liles W, Broxmeyer H, Rodger E, Wood B, Hubel K, Cooper S et al. Mobilization of hematopoietic progenitor cells in healthy volunteers by AMD3100, a CXCR4 antagonist. Blood 2003; 102: 2728–2730.

    Article  CAS  PubMed  Google Scholar 

  4. Liles W, Rodger E, Broxmeyer H, Dehner C, Badel K, Calandra G et al. Augmented mobilization and collection of CD34+ hematopoietic cells from normal human volunteers stimulated with granulocyte-colony-stimulating factor by single-dose administration of AMD3100, a CXCR4 antagonist. Transfusion 2005; 45: 295–300.

    Article  CAS  PubMed  Google Scholar 

  5. Flomenberg N, Devine S, Dipersio J, Liesveld J, McCarty J, Rowley S et al. The use of AMD3100 plus G-CSF for autologous hematopoietic progenitor cell mobilization is superior to G-CSF alone. Blood 2005; 106: 1867–1874.

    Article  CAS  PubMed  Google Scholar 

  6. Gazitt Y, Freytes C, Akay C, Badel K, Calandra G . Improved mobilization of peripheral blood CD34(+) cells and dendritic cells by AMD3100 plus granulocyte-colony-stimulating factor in non-hodgkin's lymphoma patients. Stem Cells Dev 2007; 16: 657–666.

    Article  CAS  PubMed  Google Scholar 

  7. DiPersio JF, Micallef INM, Stiff PJ, Bolwell BJ, Maziarz RT, Bridger G et al. Months report from the Phase 3 study of plerixafor+G-CSF vs placebo+G-CSF for mobilization of hematopoietic stem cell for autologous transplant in patients with NHL. Blood (ASH Ann Meet Abstr) 2008; 112: 1136.

    Google Scholar 

  8. DiPersio JF, Stadtmauer EA, Nademanee AP, Micallef INM, Stiff PJ, Bridger G et al. 12 months report from a Phase 3 study of plerixafor+G-CSF vs placebo+G-CSF for mobilization of hematopoietic stem cell for autologous transplant in patients with multiple myeloma. Blood (ASH Ann Meet Abstr) 2008; 112: 3312.

    Google Scholar 

  9. DiPersio J, Stadtmauer EA, Nademanee AP, Stiff P, Micallef I, Angell J et al. A Phase III, multicenter, randomized, double-blind, placebo-controlled, comparative trial of AMD3100 (plerixafor)+G-CSF vs G-CSF+placebo for mobilization in multiple myeloma (MM) patients for autologous hematopoietic stem cell (aHSC) transplantation. Blood (ASH Ann Meet Abstr) 2007; 110: 445.

    Google Scholar 

  10. DiPersio JF, Micallef I, Stiff PJ, Bolwell BJ, Maziarz RT, Angell J et al. A Phase III, multicenter, randomized, double-blind, placebo controlled, comparative trial of AMD3100 (plerixafor)+G-CSF vs placebo+G-CSF in non-Hodgkin's lymphoma (NHL) patients for autologous hematopoietic stem cell (aHSC) transplantation. ASH Ann Meet Abstr 2007; 110: 601.

    Google Scholar 

  11. Demirer T, Buckner C, Bensinger W . Optimization of peripheral blood stem cell mobilization. Stem Cells 1996; 14: 106–116.

    Article  CAS  PubMed  Google Scholar 

  12. Nademanee A, Sniecinski I, Schmidt GM, Dagis AC, O'Donnell MR, Snyder DS et al. High-dose therapy followed by autologous peripheral-blood stem-cell transplantation for patients with Hodgkin's disease and non-Hodgkin's lymphoma using unprimed and granulocyte colony-stimulating factor-mobilized peripheral-blood stem cells. J Clin Oncol 1994; 12: 2176–2186.

    Article  CAS  PubMed  Google Scholar 

  13. Bensinger WI, Rowley SD, Demirer T, Lilleby K, Schiffman K, Clift RA et al. High-dose therapy followed by autologous hematopoietic stem-cell infusion for patients with multiple myeloma. J Clin Oncol 1996; 14: 1447–1456.

    Article  CAS  PubMed  Google Scholar 

  14. Fu S, Liesveld J . Mobilization of hematopoietic stem cells. Blood Rev 2000; 14: 205–218.

    Article  CAS  PubMed  Google Scholar 

  15. Jansen J, Hanks S, Thompson JM, Dugan MJ, Akard LP . Transplantation of hematopoietic stem cells from the peripheral blood. J Cell Mol Med 2005; 9: 37–50.

    Article  PubMed  PubMed Central  Google Scholar 

  16. Jansen J, Thompson JM, Dugan MJ, Nolan P, Wiemann MC, Birhiray R et al. Peripheral blood progenitor cell transplantation. Ther Apher 2002; 6: 5–14.

    Article  PubMed  Google Scholar 

  17. Akard LP, Thompson JM, Dugan MJ, Wiemann M, Greenspan A, Hanks S et al. Matched-pair analysis of hematopoietic progenitor cell mobilization using G-CSF vs. cyclophosphamide, etoposide, and G-CSF: enhanced CD34+ cell collections are not necessarily cost-effective. Biol Blood Marrow Transplant 1999; 5: 379–385.

    Article  CAS  PubMed  Google Scholar 

  18. Calandra G, McCarty J, McGuirk J, Tricot G, Crocker SA, Badel K et al. AMD3100 plus G-CSF can successfully mobilize CD34+ cells from non-Hodgkin's lymphoma, Hodgkin's disease and multiple myeloma patients previously failing mobilization with chemotherapy and/or cytokine treatment: compassionate use data. Bone Marrow Transplant 2008; 41: 331–338.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Indiana Blood & Marrow Transplantation, IN, Indianapolis, USA

    M J Dugan

  2. Center for Hematologic Malignancies, Oregon Health and Science University, OR, Portland, USA

    R T Maziarz

  3. Clinical Research Division, Fred Hutchinson Cancer Research Center, WA, Seattle, USA

    W I Bensinger

  4. Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, CA, Duarte, USA

    A Nademanee

  5. Blood and Marrow Transplantation, University of Rochester Medical Center, NY, Rochester, USA

    J Liesveld

  6. Formerly of AnorMED Inc., now Genzyme Corporation, MA, Cambridge, USA

    K Badel, C Dehner, C Gibney, G Bridger & G Calandra

Authors
  1. M J Dugan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. R T Maziarz
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. W I Bensinger
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. A Nademanee
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. J Liesveld
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. K Badel
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. C Dehner
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. C Gibney
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. G Bridger
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. G Calandra
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to M J Dugan.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Dugan, M., Maziarz, R., Bensinger, W. et al. Safety and preliminary efficacy of plerixafor (Mozobil) in combination with chemotherapy and G-CSF: an open-label, multicenter, exploratory trial in patients with multiple myeloma and non-Hodgkin's lymphoma undergoing stem cell mobilization. Bone Marrow Transplant 45, 39–47 (2010). https://doi.org/10.1038/bmt.2009.119

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/bmt.2009.119

Keywords

This article is cited by

Search

Advanced search

Quick links